SCHEMBL10145455

SCHEMBL10145455

CNCC(C)(c1ccccc1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 2/20 0.46
TAAR1 Q96RJ0 2/20 0.43
MAPK1 P28482 1/20 0.41
CYP2D6 P10635 2/20 0.40
LMNA P02545 1/20 0.40
CYP3A4 P08684 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39
CYP2C19 P33261 3/20 0.39
HIF1A Q16665 1/20 0.39
ALDH1A1 P00352 2/20 0.38
ALOX15 P16050 1/20 0.38
ATM Q13315 1/20 0.38
MEN1 O00255 1/20 0.38
CYP2C9 P11712 1/20 0.38
NPY2R P49146 1/20 0.38
KMT2A Q03164 1/20 0.38
KCNA5 P22460 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27404986 0.84 KCNA5 (0.45) LMNACYP3A4CYP2C19HIF1ACYP2C9
SCHEMBL8028843 0.83 TAAR1 (0.56) KCNN4TAAR1MAPK1CYP2D6LMNA
SCHEMBL20856895 0.83 TAAR1 (0.44) KCNN4TAAR1MAPK1CYP2D6CYP3A4
SCHEMBL27016733 0.79 TAAR1 (0.46) KCNN4TAAR1MAPK1CYP2D6LMNA
SCHEMBL28333332 0.79 TAAR1 (0.46) KCNN4TAAR1MAPK1CYP2D6LMNA
SCHEMBL17610986 0.77 KCNN4 (0.43) KCNN4TAAR1MAPK1CYP2D6LMNA
SCHEMBL5142176 0.77 CYP2C19 (0.56) KCNN4TAAR1MAPK1CYP2D6LMNA
SCHEMBL1979112 0.77 NPSR1 (0.48) TAAR1MAPK1LMNACYP2C19HIF1A
SCHEMBL2903242 0.76 KCNN4 (0.46) KCNN4TAAR1MAPK1CYP2D6LMNA
Hydrochloric Acid SCHEMBL9413960 0.76 CYP2C19 (0.54) KCNN4TAAR1MAPK1LMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2592071-B1 Tricyclic heterocyclic compounds BRISTOL MYERS SQUIBB CO (US) 2019-09-18 EP disclosed
US-9775831-B2 Combinations comprising biphenyl derivatives for use in the treatment of HCV BRISTOL-MYERS SQUIBB COMPANY (US) 2017-10-03 US disclosed
US-20160166545-A1 COMBINATIONS COMPRISING BIPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF HCV BRISTOL MYERS SQUIBB CO (US) 2016-06-16 US disclosed
US-20130310373-A1 PYRIMIDINE COMPOUND ASTELLAS PHARMA INC. (JP) 2013-11-21 US disclosed
US-8524727-B2 Pyrimidine compound ASTELLAS PHARMA INC. (JP) 2013-09-03 US disclosed
US-8524727-B2 Pyrimidine compound ASTELLAS PHARMA INC. (JP) 2013-09-03 US disclosed
EP-2415765-A1 PYRIMIDINE COMPOUND Astellas Pharma Inc. (JP) 2012-02-08 EP disclosed
US-20110053912-A1 PYRIMIDINE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-03-03 US disclosed
US-20110053912-A1 PYRIMIDINE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-03-03 US disclosed
WO-2010113834-A1 PYRIMIDINE COMPOUND アステラス製薬株式会社 (JP) 2010-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166545-A1 COMBINATIONS COMPRISING BIPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF HCV HAVCR2, EIF2AK2, MAVS KCNN4 4876/4885TAAR1 4553/4885MAPK1 4432/4885
US-20110053912-A1 PYRIMIDINE COMPOUND CNR2, CNR1, P2RY2 KCNN4 3025/4885TAAR1 314/4885MAPK1 2975/4885
US-20130310373-A1 PYRIMIDINE COMPOUND CNR2, CNR1, P2RY2 KCNN4 2768/4885TAAR1 220/4885MAPK1 3218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.